Created at	Source	Raw Value	Validated value
April 22, 2021, 12:31 a.m.	usa	Incidence of composite serious adverse events (Phase I);Patients alive with grade 3 or 4 infusional toxicity (Phase II);Patients alive without grade 3, 4 infusional toxicity (Phase II);Patients not alive (Phase II)	Incidence of composite serious adverse events (Phase I);Patients alive with grade 3 or 4 infusional toxicity (Phase II);Patients alive without grade 3, 4 infusional toxicity (Phase II);Patients not alive (Phase II)
Oct. 26, 2020, 11:31 p.m.	usa	Patients alive without grade 3, 4 infusional toxicity (Phase II);Incidence of composite serious adverse events (Pilot);Patients alive with grade 3 or 4 infusional toxicity (Phase II);Patients not alive (Phase II)	Patients alive without grade 3, 4 infusional toxicity (Phase II);Incidence of composite serious adverse events (Pilot);Patients alive with grade 3 or 4 infusional toxicity (Phase II);Patients not alive (Phase II)